Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update
Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 2018 Novocure to…
Pharmaceuticals, Biotechnology and Life Sciences
Full year 2019 preliminary net revenues of $351.3 million, representing annual growth of 42 percent compared to 2018 Novocure to…
LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical…
SAN DIEGO–(BUSINESS WIRE)–#ALS—Neuropore Therapies, Inc. announced today that it has successfully completed the Phase 1 clinical trial in healthy volunteers…
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to…
DUBLIN–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr.…
– Company announces anticipated timelines for data readouts from six cabozantinib potentially label-enabling clinical studies and up to three new…
mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases mRNA-6981…
Bolstered with $200M Series A Financing, EQRx Brings Blue-Chip Investors and Life Sciences Leaders Together to Re-Make the Business of…
Potential for a Novel Chemotherapy-Free Treatment Option for People with Advanced HER2-positive, HR-positive Breast Cancer VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc.…
Potential Proof-of-Concept Data for SY-1425 in Combination with Azacitidine in RARA-Positive Relapsed or Refractory AML Patients Expected in Fourth Quarter…